{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:18:42Z","timestamp":1792649922735,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cytochrome P450 drug metabolizing enzymes are implicated in personalized medicine for two main reasons. First, inter-individual variability in CYP3A4 expression is a confounding factor during cancer treatment. Second, inhibition or induction of CYP3A4 can trigger adverse drug\u2013drug interactions. However, inflammation can downregulate CYP3A4 and other drug metabolizing enzymes and lead to altered metabolism of drugs and essential vitamins and lipids. Little is known about effects of inflammation on expression of CYP450 genes controlling drug metabolism in the skin. Therefore, we analyzed seven published microarray datasets, and identified differentially-expressed genes in two inflammatory skin diseases (melanoma and psoriasis). We observed opposite patterns of expression of genes regulating metabolism of specific vitamins and lipids in psoriasis and melanoma samples. Thus, genes controlling the turnover of vitamin D (CYP27B1, CYP24A1), vitamin A (ALDH1A3, AKR1B10), and cholesterol (CYP7B1), were up-regulated in psoriasis, whereas melanomas showed downregulation of genes regulating turnover of vitamin A (AKR1C3), and cholesterol (CYP39A1). Genes controlling abnormal keratinocyte differentiation and epidermal barrier function (CYP4F22, SULT2B1) were up-regulated in psoriasis. The up-regulated CYP24A1, CYP4F22, SULT2B1, and CYP7B1 genes are potential drug targets in psoriatic skin. Both disease samples showed diminished drug metabolizing capacity due to downregulation of the CYP1B1 and CYP3A5 genes. However, melanomas showed greater loss of drug metabolizing capacity due to downregulation of the CYP3A4 gene.<\/jats:p>","DOI":"10.3390\/pharmaceutics8010004","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T22:19:47Z","timestamp":1455833987000},"page":"4","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma"],"prefix":"10.3390","volume":"8","author":[{"given":"Venil","family":"Sumantran","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu 600095, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu 600095, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bera","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu 600095, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Sudhakar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu 600095, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"20120431","DOI":"10.1098\/rstb.2012.0431","article-title":"Human cytochromes P450 in health and disease","volume":"368","author":"Nebert","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond B"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.0022-202X.2004.23307.x","article-title":"Cytochrome P450: A Target for drug development for skin diseases","volume":"123","author":"Ahmad","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/1389200043335559","article-title":"Cytochrome P450 regulation and drug biotransformation during inflammation and infection","volume":"5","author":"Renton","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrg3394","article-title":"Reuse of public genome-wide gene expression data","volume":"14","author":"Rung","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/jid.2012.184","article-title":"Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-serve psoriasis","volume":"132","author":"Li","year":"2012","journal-title":"J.Investig.Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yao, Y., Richman, L., Morehouse, C., and de los Reyes, M. (2008). Type I interferon: Potential therapeutic target for psoriasis. PLoS ONE, 3.","DOI":"10.1371\/annotation\/fbcbcab9-2e87-4ec7-af6e-c6e9e64ad4b3"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bigler, J., Rand, H.A., Kerkof, K., Timour, M., and Russell, C.B. (2013). Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052242"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/jid.2013.197","article-title":"Transcriptome profiling identifies HMAG2 as a biomarker of melanoma progression and prognosis","volume":"133","author":"Raskin","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kabbarah, O., Nogueira, C., Feng, B., and Nazarian, R.M. (2010). Integrative genome comparison of primary and metastatic melanomas. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010770"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","article-title":"Novel genes associated with malignant melanoma but not benign melanocytic lesions","volume":"11","author":"Talantov","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_11","first-page":"11","article-title":"BRB analysis of gene expression data using BRB-Array Tools","volume":"4","author":"Simon","year":"2007","journal-title":"Cancer Inform."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tian, S., Krueger, J.G., Li, K., Jabbari, A., and Brodmerkel, C. (2012). Meta-analysis derived (MAD) transcriptome of psoriasis defines the \u2018\u2018Core\u2019\u2019 pathogenesis of disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044274"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1562\/2005-02-02-IR-430","article-title":"The vitamin D3 pathway in human skin and its role for regulation of biological processes","volume":"81","author":"Lehmann","year":"2005","journal-title":"Photochem. Photobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03410.x","article-title":"A comprehensive review of biomarkers in psoriasis","volume":"34","author":"Rashmi","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0705659105","article-title":"Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10","volume":"104","author":"Gallego","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","first-page":"743","article-title":"Differential expression of type 2 3\u03b1\/type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system","volume":"3","author":"Park","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1158\/0008-5472.CAN-04-1129","article-title":"Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: A possible explanation for tumor preventive action of retinoids","volume":"64","author":"Mrass","year":"2004","journal-title":"Cancer Res."},{"key":"ref_18","first-page":"124","article-title":"Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states","volume":"11","author":"Kelly","year":"2011","journal-title":"Mol. Invent."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbalip.2013.08.020","article-title":"The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier","volume":"1841","author":"Thomas","year":"2014","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbalip.2013.11.009","article-title":"Role of cholesterol sulfate in epidermal structure and function: Lessons from X-linked ichthyosis","volume":"1841","author":"Elias","year":"2014","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yang, X., Xu, Y., Guo, F., Ning, Y., Zhi, X., Yin, L., and Li, X. (2013). Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo . PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060853"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.freeradbiomed.2011.11.033","article-title":"Aldehyde dehydrogenases and cell proliferation","volume":"52","author":"Muzio","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BJ20140624","article-title":"Mouse aldehyde dehydrogenase ALDH3B2 is localized to lipid droplets via two C-terminal tryptophan residues and lipid modification","volume":"465","author":"Kitamura","year":"2015","journal-title":"Biochem. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1194\/jlr.M039404","article-title":"Regulation of human class I alcohol dehydrogenases by bile acids","volume":"54","author":"Langhi","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.redox.2012.12.001","article-title":"Oxysterols in the pathogenesis of major chronic disease","volume":"31","author":"Poli","year":"2013","journal-title":"Redox Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2362.2002.00931.x","article-title":"Oxysterols induce interleukin-1beta production in human macrophages","volume":"32","author":"Rosklint","year":"2002","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16764","DOI":"10.1073\/pnas.0909142106","article-title":"25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production","volume":"106","author":"Bauman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/18715206113139990308","article-title":"Cytochromes p450 and skin cancer: Role of local endocrine pathways","volume":"14","author":"Slominski","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jsbmb.2007.03.026","article-title":"Dehydroepiandrosterone 7 alpha-hydroxylation in human tissues: Possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes","volume":"104","author":"Hennebert","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_30","first-page":"10187","article-title":"Association of CYP39A1, RUNX2 and oxidized alpha-1 antitrypsin expression in relation to cholangiocarcinoma progression","volume":"23","author":"Khenjanta","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1152\/ajpheart.00071.2006","article-title":"Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury","volume":"291","author":"Nithipatikom","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"35184","DOI":"10.1074\/jbc.M301666200","article-title":"Epoxyeicosatrienoic acids activate transglutaminases in situ and induce cornification of epidermal keratinocytes","volume":"278","author":"Ladd","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/03602530600688503","article-title":"CYP4B1: An enigmatic P450 at the interface between xenobiotic and endobiotic metabolism","volume":"38","author":"Baer","year":"2006","journal-title":"Drug Metab. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/BJ20140813","article-title":"Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol","volume":"465","author":"Wiek","year":"2015","journal-title":"Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/mol.58.6.1341","article-title":"Identification of humancytochromeP450s involved in the formation of all-trans-retinoicacid principal metabolites","volume":"58","author":"Marill","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138920007779815986","article-title":"Transcriptional regulation and expression of CYP3A4 in hepatocytes","volume":"8","author":"Jover","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0027-5107(02)00333-0","article-title":"Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies","volume":"523\u2013524","author":"Guengerich","year":"2003","journal-title":"Mutat. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2004.tb03162.x","article-title":"Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1","volume":"95","author":"Shimada","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1523-1747.2000.00876.x","article-title":"Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1","volume":"114","author":"Katiyar","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.96.5.1977","article-title":"Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas","volume":"96","author":"Buters","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10239.x","article-title":"Noninvasive genomic detection of melanoma","volume":"164","author":"Wachsman","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1158\/0008-5472.CAN-09-1691","article-title":"Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis","volume":"69","author":"Saini","year":"2009","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-2952(01)00643-8","article-title":"Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance","volume":"62","author":"McFadyen","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"van Eijl, S., Zhu, Z., Cupitt, J., Gierula, M., G\u00f6tz, C., Fritsche, E., and Edwards, R.J. (2012). Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041721"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2125.2012.04373.x","article-title":"Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity","volume":"75","author":"Brennan","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00296-012-2423-3","article-title":"Interleukin-6 and cytochrome-P450, reason for concern?","volume":"32","author":"Kimm","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_50","first-page":"38","article-title":"Adverse reactions of biological therapy for psoriasis","volume":"119","author":"Voicu","year":"2015","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Iasi."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: Effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","article-title":"Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: A phase I\/II pharmacokinetic interaction study","volume":"68","author":"Flaherty","year":"2011","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/8\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:19:15Z","timestamp":1760210355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/8\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["pharmaceutics8010004"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics8010004","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,17]]}}}